FDA rolls out inaugural pathway for tailor-made rare-disease drugs
TL;DR
The FDA unveiled a new plausible mechanism pathway to approve medicines crafted for patients’ individual mutations, moving the idea from preview into formal policy and potentially enabling gene-editing–based and other targeted therapies for rare diseases.
Topics:businesshealth#fda#gene-editing#health#note-only-five-tags-allowed-extra-included-only-if-needed#personalized-medicine#rare-disease#regulatory-policy
- FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications statnews.com
- FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases HHS.gov
- Opinion | FDA: How We’re Approving More Drugs to Treat Rare Diseases WSJ
- The FDA creates a quicker path for gene therapies NPR
- FDA proposes new system for approving customized drugs and therapies for rare diseases AP News
Want the full story? Read the original reporting
Read on statnews.com